These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37358515)

  • 1. Cardiac Transplantation: Physiology and Natural History of the Transplanted Heart.
    Asleh R; Alnsasra H; Villavicencio MA; Daly RC; Kushwaha SS
    Compr Physiol; 2023 Jun; 13(3):4719-4765. PubMed ID: 37358515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac rehabilitation for heart transplant patients: Considerations for exercise training.
    Squires RW; Bonikowske AR
    Prog Cardiovasc Dis; 2022; 70():40-48. PubMed ID: 34942234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients.
    Bergh N; Gude E; Bartfay SE; K Andreassen A; Arora S; Dahlberg P; Dellgren G; Gullestad L; Gustafsson F; Karason K; Rådegran G; Bollano E; Andersson B
    ESC Heart Fail; 2020 Apr; 7(2):567-576. PubMed ID: 32059083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latest developments in heart transplantation: a review.
    Andrew J; Macdonald P
    Clin Ther; 2015 Oct; 37(10):2234-41. PubMed ID: 26497799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise following heart transplantation.
    Braith RW; Edwards DG
    Sports Med; 2000 Sep; 30(3):171-92. PubMed ID: 10999422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
    Asleh R; Briasoulis A; Kremers WK; Adigun R; Boilson BA; Pereira NL; Edwards BS; Clavell AL; Schirger JA; Rodeheffer RJ; Frantz RP; Joyce LD; Maltais S; Stulak JM; Daly RC; Tilford J; Choi WG; Lerman A; Kushwaha SS
    J Am Coll Cardiol; 2018 Feb; 71(6):636-650. PubMed ID: 29420960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allograft diastolic dysfunction and chronotropic incompetence limit cardiac output response to exercise two to six years after heart transplantation.
    Kao AC; Van Trigt P; Shaeffer-McCall GS; Shaw JP; Kuzil BB; Page RD; Higginbotham MB
    J Heart Lung Transplant; 1995; 14(1 Pt 1):11-22. PubMed ID: 7727459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the development of cardiac allograft vasculopathy.
    Seki A; Fishbein MC
    Cardiovasc Pathol; 2014; 23(5):253-60. PubMed ID: 24972526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung function and cardiopulmonary exercise performance after heart transplantation: influence of cardiac allograft vasculopathy.
    Schwaiblmair M; von Scheidt W; Uberfuhr P; Reichart B; Vogelmeier C
    Chest; 1999 Aug; 116(2):332-9. PubMed ID: 10453859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
    Asimacopoulos EP; Garbern JC; Gauvreau K; Blume ED; Daly KP; Singh TP
    Transplantation; 2020 Jan; 104(1):e31-e37. PubMed ID: 31568274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens.
    Ueyama H; Kuno T; Takagi H; Alvarez P; Asleh R; Briasoulis A
    Heart Fail Rev; 2022 May; 27(3):869-877. PubMed ID: 32424550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
    Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
    J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation.
    Ram E; Lavee J; Tenenbaum A; Klempfner R; Fisman EZ; Maor E; Ovdat T; Amunts S; Sternik L; Peled Y
    Cardiovasc Diabetol; 2019 Sep; 18(1):118. PubMed ID: 31526382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac allograft vasculopathy in pediatric heart transplant recipients does early-onset portend a worse prognosis?
    Khoury M; Conway J; Gossett JG; Edens E; Soto S; Cantor R; Koehl D; Barnes A; Exil V; Glass L; Kirklin JK; Zuckerman WA
    J Heart Lung Transplant; 2022 May; 41(5):578-588. PubMed ID: 35172937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-immune risk predictors of cardiac allograft vasculopathy: Results from the U.S. organ procurement and transplantation network.
    Fluschnik N; Geelhoed B; Becher PM; Schrage B; Brunner FJ; Knappe D; Bernhardt AM; Blankenberg S; Kobashigawa J; Reichenspurner H; Schnabel RB; Magnussen C
    Int J Cardiol; 2021 May; 331():57-62. PubMed ID: 33571561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation.
    Badano LP; Miglioranza MH; Edvardsen T; Colafranceschi AS; Muraru D; Bacal F; Nieman K; Zoppellaro G; Marcondes Braga FG; Binder T; Habib G; Lancellotti P;
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):919-48. PubMed ID: 26139361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction model for cardiac allograft vasculopathy: Comparison of three multivariable methods.
    Kransdorf EP; Loghmanpour NA; Kanwar MK; Temkit MH; Stehlik J
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of everolimus as de novo immunosuppressant on the cardiac allograft vasculopathy in heart transplant recipients.
    Choi HI; Kang DY; Kim MS; Lee SE; Ahn JM; Lee JY; Kim YH; Park DW; Jung SH; Kim JJ
    Atherosclerosis; 2022 Sep; 357():1-8. PubMed ID: 35981436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.